Category: News Well
Content tagged to appear in the middle column of the home page
Candidates in the race for Massachusetts governor race tell MassDevice.com that they're for a repeal of the medical device tax and would support exploring a potential offset for Bay State medtech companies.
The next Massachusetts governor won't be spending any political capital defending the medical device tax, a 2.3% excise tax on U.S. medtech sales. Both of the leading candidates told MassDevice.com yesterday that they would push for a federal appeal and consider a tax credit to offset the levy.
The FDA's less-stringent 510(k) clearance process comes under fire (again) in a pair of new studies.
NEW YORK (Reuters Health) - Information on the safety and effectiveness of medical devices before and after they are cleared by U.S. health regulators can be improved, according to 2 new studies.
Tengion puts itself and its organ regeneration technology on the auction block, hiring Jefferies LLC to explore "strategic alternatives."
Tengion, TNGN, Jefferies, organ regeneration, kidney
Tengion (NSDQ:TNGN) said it's hired Jefferies to assess "all strategic alternatives," corporate shorthand for putting the Winston-Salem, N.C.-based company and its organ regeneration technology on the auction block.
Mitralign reports the 1st-in-human use of its minimally invasive device to treat tricuspid valve regurgitation under a compassionate use allowance in Germany.
Mitralign said today that surgeons in Germany implanted its tricuspid valve repair device in its 1st patient, under a "compassionate use" allowance in Germany.
Cohealo reports a $3.2 million debt round for the software it's developing to help hospitals manage their shared medical device inventory.
Cohealo reported raising $3.1 million of a hoped-for $5.8 million in debt financing as it develops software to help hospitals manage their shared medical device inventory.
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
CVRx adds CE Mark approval for treating heart failure patients to its European Union approval for hypertension treatment using its Barostim Neo device.
CVRx said today that it won CE Mark approval in the European Union for its Barostim Neo device to treat heart failure patients using vagus nerve stimulation.